Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 6/2003

01.12.2003 | Original Article

In vitro cell growth pharmacodynamic studies: a new nonparametric approach to determining the relative importance of drug concentration and treatment time

verfasst von: Massimiliano Germani, Paolo Magni, Giuseppe De Nicolao, Italo Poggesi, Aurelio Marsiglio, Dario Ballinari, Maurizio Rocchetti

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2003

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The effect of an anticancer treatment on tumor cell proliferation in vitro can be described as a three-dimensional surface where the inhibitory effect is related to drug concentration and treatment time. The analysis of this kind of response surface could provide critical information: for example, it could indicate whether a prolonged exposure to a low concentration of an anticancer agent will produce a different effect from exposure to higher concentrations for a shorter period of time. The parametric approach available in the literature was not flexible enough to accommodate the behavior of the response surface in some of the data sets collected as part of our research programs. Therefore, a new, general, nonparametric approach was developed.

Methods

The response surface of the inhibition of cell-based tumor growth was described using a radial basis function neural network (RBF-NN). The RBF-NN was trained using regularization theory, which provided the initialization of a constrained quadratic optimization algorithm that imposes monotonicity of the surface with respect to both concentration and exposure time.

Results

In the two analyzed cases (doxorubicin and flavopiridol), the proposed method was accurate and reliable in describing the inhibition surface of tumor cell growth as a function of drug concentration and exposure time. Residuals were small and unbiased. The new method improved on the parametric approach when the relative importance of drug concentration and exposure time in determining the overall effect was not constant across the experimental data.

Conclusions

The proposed RBF-NN can be reliably applied for the analysis in cell-based tumor growth inhibition studies. This approach can be used for optimizing the administration regimens to be adopted in vivo. The use of this methodology can be easily extended to any cell-based experiment, in which the outcome can be seen as a function of two experimental variables.
Literatur
1.
Zurück zum Zitat Bertero M (1989) Linear inverse problems and ill-posed problems. Adv Electronics Electron Phys 75:1–120 Bertero M (1989) Linear inverse problems and ill-posed problems. Adv Electronics Electron Phys 75:1–120
2.
Zurück zum Zitat Dayhoff JE, DeLeo JM (2001) Artificial neural networks, opening the black box. Cancer 91:1615–1635CrossRefPubMed Dayhoff JE, DeLeo JM (2001) Artificial neural networks, opening the black box. Cancer 91:1615–1635CrossRefPubMed
3.
Zurück zum Zitat De Nicolao G, Saracino G, Cobelli C (1997) Nonparametric input estimation in physiological systems: problems, methods, and case studies. Automatica 33:851–870CrossRef De Nicolao G, Saracino G, Cobelli C (1997) Nonparametric input estimation in physiological systems: problems, methods, and case studies. Automatica 33:851–870CrossRef
4.
Zurück zum Zitat Fletcher R (1981) Practical methods of optimization, 2nd edn. John Wiley & Sons, New York Fletcher R (1981) Practical methods of optimization, 2nd edn. John Wiley & Sons, New York
5.
Zurück zum Zitat Gill PE, Murray W, Wright MH (1981) Practical optimization. Academic Press, San Diego London Gill PE, Murray W, Wright MH (1981) Practical optimization. Academic Press, San Diego London
6.
Zurück zum Zitat Girosi F, Jones M, Poggio T (1995) Regularization theory and neural networks architectures. Neural Comput 7:219–269 Girosi F, Jones M, Poggio T (1995) Regularization theory and neural networks architectures. Neural Comput 7:219–269
7.
Zurück zum Zitat Golub GH, Heath M, Wahba G (1979) Generalized cross-validation as a method for choosing a good ridge parameter. Technometrics 21:215–224 Golub GH, Heath M, Wahba G (1979) Generalized cross-validation as a method for choosing a good ridge parameter. Technometrics 21:215–224
8.
Zurück zum Zitat Kalns JE, Millenbaugh NJ, Wientjes MG, Au JL-S (1995) Design and analysis of in vitro antitumor pharmacodynamic studies. Cancer Res 55:5315–5322PubMed Kalns JE, Millenbaugh NJ, Wientjes MG, Au JL-S (1995) Design and analysis of in vitro antitumor pharmacodynamic studies. Cancer Res 55:5315–5322PubMed
9.
Zurück zum Zitat Millenbaugh NJ, Wientjes NG, Au JL-S (2000) A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect. Cancer Chemother Pharmacol 45:265–272CrossRefPubMed Millenbaugh NJ, Wientjes NG, Au JL-S (2000) A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect. Cancer Chemother Pharmacol 45:265–272CrossRefPubMed
10.
Zurück zum Zitat Poggio T, Girosi F (1990) Networks for approximation and learning. Proc IEEE 78:1481–1497CrossRef Poggio T, Girosi F (1990) Networks for approximation and learning. Proc IEEE 78:1481–1497CrossRef
11.
Zurück zum Zitat Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR (1990) Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82:1113–1118PubMed Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR (1990) Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82:1113–1118PubMed
12.
Zurück zum Zitat Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112PubMed Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112PubMed
Metadaten
Titel
In vitro cell growth pharmacodynamic studies: a new nonparametric approach to determining the relative importance of drug concentration and treatment time
verfasst von
Massimiliano Germani
Paolo Magni
Giuseppe De Nicolao
Italo Poggesi
Aurelio Marsiglio
Dario Ballinari
Maurizio Rocchetti
Publikationsdatum
01.12.2003
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 6/2003
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-003-0688-7

Weitere Artikel der Ausgabe 6/2003

Cancer Chemotherapy and Pharmacology 6/2003 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.